世卫组织支持的审查证实,GLP-1药物造成体重大幅度减重,但副作用和成本限制。 WHO-backed review confirms GLP-1 drugs cause significant weight loss, but side effects and cost limit access.

世界卫生组织委托进行的新Cochrane评价证实，GLP-1药物——替泽帕肽、索马鲁肽和利拉鲁肽——在肥胖人群中导致显着、持续的体重减轻，替泽帕肽在18个月内减轻约16%，索马鲁肽在两年内减轻约11%，利拉鲁肽在一段时间内减轻4-5%。 New Cochrane reviews commissioned by the WHO confirm that GLP-1 drugs—tirzepatide, semaglutide, and liraglutide—cause significant, sustained weight loss in people with obesity, with tirzepatide showing about 16% loss over 18 months, semaglutide around 11% over two years, and liraglutide 4–5% over time. 尽管胃肠道副作用很常见,可能导致停产,但所有三种减肥都比安慰剂多。 All three reduce weight more than placebo, though gastrointestinal side effects are common and may lead to discontinuation. 长期安全数据有限,大多数研究都是由工业资助的,而且尽管专利即将到期和可使用通用专利,但由于费用高昂,获取机会仍受到限制。 Long-term safety data are limited, most studies are industry-funded, and access remains restricted due to high costs, despite upcoming patent expirations and generic availability.